Pregnancy outcome after in utero exposure to baclofen: an ENTIS collaborative study (Baclofen and pregnancy)

04/07/2014
30/01/2025
EU PAS number:
EUPAS6934
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS6934

Study ID

16381

Official title and acronym

Pregnancy outcome after in utero exposure to baclofen: an ENTIS collaborative study (Baclofen and pregnancy)

DARWIN EU® study

No

Study countries

France
Germany
Israel
Italy
Netherlands
United Kingdom

Study description

Objective: To evaluate the risk of early in utero exposure to baclofen and to describe neonatal symptoms after 3rd trimester baclofen exposure. Design: all prospectively assessed cases collected from 1st January 1990 up to 28th February 2012 with baclofen exposure during the first trimester of pregnancy.Study group: pregnant women exposed to baclofen between week 4 and week 12 of pregnancy and with prospectively ascertained outcome. Patients exposed to major teratogens (acitretin, isotretinoin, methotrexate, mycophenolate, thalidomide, valproic acid) or patients with malignancies or malignancy-related conditions are excluded. General control group: pregnant women exposed to a non-teratogenic agent with prospectively ascertained outcome and same exclusion criteria as above. Patients from both groups are matched according to maternal age ± 2 years, gestational age at inclusion ± 2 weeks, year of counseling ± 2 years, TIS or country with 3 controls per case.Primary objectives: Rate of major birth defects, rate of spontaneous abortion.Secondary objectives: Intrauterine growth retardation (IUGR) in malformed and non-malformed newborns, prematurity rate (< 37 gestational weeks), rate of elective terminations of pregnancy (ETOPs). Description of postnatal symptoms.Analysis will consider counfounders with adjustments for parity, previous spontaneous abortions, previous children/fetuses with major birth defects, tobacco, alcohol intake.Statistical analysis.- Continuous endpoints comparison: Student's t test. - Categorical endpoints comparison: χ² test or Fisher's exact test when assumptions for χ² are not met. - If a difference is pointed out: logistic regression analysis taking into account all identified possible confounding factors.With 100 exposed cases the study has a 80% power of detecting a 3.5-fold increase in malformation rate, assuming a 3% baseline risk

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Nathalie BERNARD

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

ENTIS, ACRPV
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable